Luxna Biotech Co. Ltd.

Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaboration agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter “Servier”) for drug discovery research in the field of neurological diseases. Under the collaboration agreement, Luxna’s breakthrough xeno nucleic acid technology (hereinafter "Luxna XNAs Technology") are utilized to optimize Servier’s lead antisense oligonucleotide (hereinafter "ASO") compounds directed against a potentially transformative therapeutic target in neurological diseases in a short period of time. This collaboration for drug discovery research with Servier will accelerate the development and practical application of oligonucleotide therapies using Luxna XNAs Technology. About Luxna XNAs Technology Luxna XNAs Technology collectively means an innovative nucleic acid group of AmNA™, scpBNA™, GuNA™ and 5’-CP™ originated in Professor Obika’s laboratory at the Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry. Luxna XNAs Technology could make available ASOs with high activity and low toxicity, by taking advantage of its characteristics of strong binding to mRNA and/or reduced toxicity. About Servier Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, source of inspiration every day. As a world leader in cardiology, Servier’s ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology. Neuroscience and Immuno-inflammation are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries, achieved a revenue of €4.9 billion in 2022, and invests over 20% of its brand-name revenue in Research and Development every year. More information on the new Group website: servier.com Follow us on social media: LinkedIn, Facebook, Twitter, Instagram About Luxna Biotech Co., Ltd. Luxna is a biotech founded to develop safer and more effective oligonucleotide therapies (OTs) for practical use using the drug discovery platform based on modified nucleic acids originated at Osaka University. Our purpose is to bring OTs for patients with difficult-to-treat diseases. We actively collaborate with several pharmaceutical companies in developing new and effective OTs as well as advancing our own.